Theravance Biopharma Files 8-K: Other Events & Exhibits
Ticker: TBPH · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1583107
| Field | Detail |
|---|---|
| Company | Theravance Biopharma, Inc. (TBPH) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, exhibits
TL;DR
Theravance Biopharma filed an 8-K for routine filings, no major news.
AI Summary
On August 25, 2025, Theravance Biopharma, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or transactions detailed in the provided excerpt. The company is incorporated in the Cayman Islands and its principal executive offices are located in South San Francisco, California.
Why It Matters
This 8-K filing indicates Theravance Biopharma is submitting routine or supplementary documentation to the SEC, rather than announcing a major corporate event.
Risk Assessment
Risk Level: low — The filing appears to be routine administrative or exhibit submission, not indicating any immediate material change or risk.
Key Players & Entities
- Theravance Biopharma, Inc. (company) — Registrant
- August 25, 2025 (date) — Date of earliest event Reported
- Cayman Islands (location) — State or Other Jurisdiction of Incorporation
- 001-36033 (identifier) — Commission File Number
- 98-1226628 (identifier) — I.R.S. Employer Identification Number
- Theravance Biopharma US, LLC (company) — Mailing Address Entity
- South San Francisco, CA 94080 (location) — Principal Executive Offices Address
- 650-808-6000 (phone_number) — Principal Executive Offices Phone Number
FAQ
What is the primary purpose of this 8-K filing by Theravance Biopharma, Inc.?
The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The date of the earliest event reported is August 25, 2025.
Where is Theravance Biopharma, Inc. incorporated?
Theravance Biopharma, Inc. is incorporated in the Cayman Islands.
What is the Commission File Number for Theravance Biopharma, Inc.?
The Commission File Number is 001-36033.
What are the principal executive offices of Theravance Biopharma, Inc.?
The principal executive offices are located at c/o Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA 94080.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-08-25 06:04:02
Key Financial Figures
- $0.00001 — e on which registered Ordinary Share $0.00001 Par Value TBPH NASDAQ Global Marke
Filing Documents
- tm2524263d1_8k.htm (8-K) — 24KB
- tm2524263d1_ex99-1.htm (EX-99.1) — 25KB
- tm2524263d1_ex99-1img01.jpg (GRAPHIC) — 4KB
- 0001104659-25-082048.txt ( ) — 226KB
- tbph-20250825.xsd (EX-101.SCH) — 3KB
- tbph-20250825_lab.xml (EX-101.LAB) — 33KB
- tbph-20250825_pre.xml (EX-101.PRE) — 22KB
- tm2524263d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On August 25, 2025, Theravance Biopharma, Inc. (NASDAQ: TBPH) announced that it completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated August 25, 2025 104 Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. THERAVANCE BIOPHARMA, INC. Date: August 25, 2025 By: /s/ Aziz Sawaf Aziz Sawaf Senior Vice President and Chief Financial Officer